On October 4, 2023 Vycellix, Inc., a transformational cell and gene engineering company with the mission to integrate its process-enhancing tools into the development and commercialization of next-generation, donor-derived medicines, including off-the-shelf T cell and natural killer (NK) cell-based cancer therapeutics, reported that its scientific leadership delivered multiple presentations at NK2023 in Oslo, Norway, highlighting the Company’s proprietary platforms to optimize and improve cell therapy manufacturing and treatment outcomes (Press release, Vycellix, OCT 4, 2023, View Source;utm_medium=rss&utm_campaign=vycellix-cell-therapy-platforms-featured-at-nk2023-natural-killer-cell-meetings-in-norway [SID1234635653]). Vycellix’s founding medical scientists and SAB members moderated and participated in multiple NK cell sessions and new data were disclosed in a series of poster presentations. NK2023 was the 20th Annual Meeting arranged by the Society of Natural Immunity.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Vycellix’s senior scientific team reported new data and results in the following posters:
"Plasma Membrane Embedded System for Spaciotemporal Controlled Payload Delivery by Natural Killer Cells", VY-GAGE platform presented by Vycellix senior consulting scientist, Dara Mohammad, Ph.D., Karolinska Institutet, Stockholm, Sweden
"VY-GAGE is a novel peptide capable of delivering multiple disease-targeting payloads specifically to tumor sites, including deploying potent BiKEs (bispecific killer cell engagers) and CARs (chimeric antigen receptors). We have shown this approach to work in pre-clinical models by loading GAGE into NK cells. As a broad platform, we look forward to demonstrating the adaptability of this strategy in many other kinds of cells, including T cells. Our aim is to develop highly-targeted, highly-specific cell therapies that can deliver high doses of disease-targeting agents, but are also safer and more effective by minimizing ‘on-target, off-tumor’ adverse events," reported Dr. Mohammad.
"Generation of Universal Cellular Grafts Utilizing Signaling-Deficient Membrane-Bound CD45", VY-UC platform presented by Vycellix senior consulting scientist, Alamdar Hussain, Ph.D., Karolinska Institutet, Stockholm, Sweden
"Our VY-UC data show that the insertion of a novel CD45-engager transduced into virtually any cell represents a compelling alternative to complex and costly gene-editing systems such as CRISPR-Cas9 to engineer fully immune privileged cells. When we introduce VY-UC into donor cells and deliver to host, functional immune synapse formation is prevented resulting in abrogation of cellular immune response, thus, eliminating the risk of graft rejection. Importantly, our VY-UC engineered donor cells demonstrate persistence, retention of function, and avoidance of host immune rejection," reported Dr. Hussain.
Vycellix’s platforms were all discovered by scientists at the world-renowned Karolinska Institutet (KI) in Stockholm, Sweden. The Company is also a collaborative partner in "NextGenNK", an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI and funded by Sweden’s innovations agency, Vinnova. KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine.